参考文献
1: Feng L, Yao HP, Zhou YQ, Zhou J, Zhang R, Wang MH. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. J Exp Clin Cancer Res. 2016 Apr 22;35:70. doi: 10.1186/s13046-016-0347-6. Erratum in: J Exp Clin Cancer Res. 2016;35(1):95. PubMed PMID: 27102688; PubMed Central PMCID: PMC4840490.
2: Li S, Lu C, Chang X, Shen Y. Constitutive overexpression of asm18 increases the production and diversity of maytansinoids in Actinosynnema pretiosum. Appl Microbiol Biotechnol. 2016 Mar;100(6):2641-9. doi: 10.1007/s00253-015-7127-7. Epub 2015 Nov 17. PubMed PMID: 26572523.
3: Mang Y, Zhao Z, Zeng Z, Wu X, Li Z, Zhang L. Efficient elimination of CD103-expressing cells by anti-CD103 antibody drug conjugates in immunocompetent mice. Int Immunopharmacol. 2015 Jan;24(1):119-27. doi: 10.1016/j.intimp.2014.11.004. Epub 2014 Nov 15. PubMed PMID: 25467246.
4: Barginear MF, John V, Budman DR. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. Mol Med. 2013 Jan 22;18:1473-9. doi: 10.2119/molmed.2012.00302. PubMed PMID: 23196784; PubMed Central PMCID: PMC3563710.
5: Siyu-Mao, Hong-Chen, Li-Chen, Chuanxi-Wang, Wei-Jia, Xiaoming-Chen, Huangjian-Yang, Wei-Huang, Wei-Zheng. Two novel ansamitocin analogs from Actinosynnema pretiosum. Nat Prod Res. 2013;27(17):1532-6. doi: 10.1080/14786419.2012.733388. Epub 2012 Oct 15. PubMed PMID: 23061718.
6: Segraves NL, Yazzie D, Deese AJ. An isolable acyclic hemiacetal of ansamitocin P-3. Magn Reson Chem. 2012 Mar;50(3):256-9. doi: 10.1002/mrc.2876. Epub 2012 Feb 28. PubMed PMID: 22374862.
7: Edwards A, Gladstone M, Yoon P, Raben D, Frederick B, Su TT. Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cells. Dis Model Mech. 2011 Jul;4(4):496-503. doi: 10.1242/dmm.006486. Epub 2011 Apr 18. PubMed PMID: 21504911; PubMed Central PMCID: PMC3124055.
8: Wei GZ, Bai LQ, Yang T, Ma J, Zeng Y, Shen YM, Zhao PJ. A new antitumour ansamitocin from Actinosynnema pretiosum. Nat Prod Res. 2010 Jul;24(12):1146-50. doi: 10.1080/14786410902916552. PubMed PMID: 20582809.
9: Moss SJ, Bai L, Toelzer S, Carroll BJ, Mahmud T, Yu TW, Floss HG. Identification of asm19 as an acyltransferase attaching the biologically essential ester side chain of ansamitocins using N-desmethyl-4,5-desepoxymaytansinol, not maytansinol, as its substrate. J Am Chem Soc. 2002 Jun 12;124(23):6544-5. PubMed PMID: 12047169.
10: Bénéchie M, Khuong-Huu F. Total Synthesis of (-)-Maytansinol. J Org Chem. 1996 Oct 4;61(20):7133-7138. PubMed PMID: 11667616.
11: Sawada T, Kato Y, Kobayashi H, Hashimoto Y, Watanabe T, Sugiyama Y, Iwasaki S. A fluorescent probe and a photoaffinity labeling reagent to study the binding site of maytansine and rhizoxin on tubulin. Bioconjug Chem. 1993 Jul-Aug;4(4):284-9. PubMed PMID: 8218485.
12: Kawai A, Akimoto H, Kozai Y, Ootsu K, Tanida S, Hashimoto N, Nomura H. Chemical modification of ansamitocins. III. Synthesis and biological effects of 3-acyl esters of maytansinol. Chem Pharm Bull (Tokyo). 1984 Sep;32(9):3341-51. PubMed PMID: 6441645.
13: Nakahama K, Izawa M, Asai M, Kida M, Kishi T. Microbial conversion of ansamitocin. J Antibiot (Tokyo). 1981 Dec;34(12):1581-6. PubMed PMID: 7333971.
14: Ikeyama S, Takeuchi M. Antitubulin activities of ansamitocins and maytansinoids. Biochem Pharmacol. 1981 Sep 1;30(17):2421-5. PubMed PMID: 21043240.
15: Kupchan SM, Sneden AT, Branfman AR, Howie GA, Rebhun LI, McIvor WE, Wang RW, Schnaitman TC. Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids. J Med Chem. 1978 Jan;21(1):31-7. PubMed PMID: 563462.
16: Kupchan SM, Branfman AR, Sneden AT, Verma AK, Dailey RG Jr, Komoda Y, Nagao Y. Letter: Novel maytansinoids. Naturally occurring and synthetic antileukemic esters of maytansinol. J Am Chem Soc. 1975 Sep 3;97(18):5294-5. PubMed PMID: 1165364.
